title: [The application of laripront in the pediatric otorhinolaryngological practice].
abstract: The objective of the present study was to estimate the efficacy of laripront intended for the treatment of inflammatory diseases of the laryngopharynx in the children. Available for the observation were 50 patients aged between 4 and 14 years suffering from the following ENT pathologies: adenoiditis, lacunar tonsillitis, acute laryngitis, chronic tonsillitis, oropharyngeal candidiasis, chronic hypertrophic pharyngitis, atrophic pharyngolaryngitis after the chemical burn of the mouse cavity and laryngopharynx or in the case of gastroesophageal reflux disease. All the patients enjoyed the positive outcome of the treatment that was especially efficacions in the patients with acute pathologies. No adverse effects of the treatment were documented.
authors.forename: V P
authors.initials: VP
authors.lastname: Chistiakova
authors.forename: L L
authors.initials: LL
authors.lastname: Miasnikov
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003868:Dequalinium / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D016903:Drug Monitoring; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007013:Hypopharynx / Q000187:drug effects / Q000382:microbiology; D008297:Male; D009113:Muramidase / Q000008:administration & dosage / Q000009:adverse effects; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D012141:Respiratory Tract Infections / Q000145:classification / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D013607:Tablets; D003868:Dequalinium; D009113:Muramidase